Comparative Pharmacology
Head-to-head clinical analysis: AEMCOLO versus DIFICID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEMCOLO versus DIFICID.
AEMCOLO vs DIFICID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEMCOLO (crizotinib) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and mesenchymal-epithelial transition factor (MET). It inhibits ALK and ROS1 phosphorylation, blocking downstream signaling pathways involved in cell proliferation and survival.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
AEMCOLO (rifamycin) delayed-release tablets: 600 mg orally twice daily for 3 days. Take with or without food.
200 mg (tablet) orally twice daily for 10 days.
None Documented
None Documented
Terminal elimination half-life is approximately 18-22 hours, supporting once-daily dosing for maintained intraluminal concentrations.
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
Primarily fecal elimination as unchanged drug; approximately 90% of a dose is recovered in feces, with less than 1% excreted unchanged in urine. Biliary excretion accounts for the remainder.
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Category C
Category C
Antibiotic
Antibiotic